Cremer-Schaeffer Peter
Anasthesiol Intensivmed Notfallmed Schmerzther. 2021 Apr;56(4):297-302. doi: 10.1055/a-1215-4054. Epub 2021 Apr 22.
In 2017, the legislator created a special regulation for medical cannabis in Germany. Medical cannabis can also be prescribed without marketing authorization at the expense of the statutory health insurance, if other forms of therapy are not sufficiently effective. Before starting therapy with a cannabis medicine outside of approved indications, an application for reimbursement must be submitted to the health insurance company. Cannabis medicines are mainly prescribed for the treatment of chronic pain. There are some rules to be observed when prescribing cannabis medicines: The information according to Section 9 of the Narcotic Drugs Prescription Ordinance must be complete and clear. Data on the therapeutic success and the safe use of the cannabis medicines are collected in a five-year follow-up survey. According to first interim results of this survey, many side effects have an influence on the vigilance of patients. The risk of falling is increased, especially in older patients. In the medium term, the special regulation described above should become dispensable due to the approval of cannabis-based finished medicinal products.
2017年，德国立法者针对医用大麻制定了一项特殊规定。如果其他治疗方式效果不佳，医用大麻也可以在没有上市许可的情况下开具，费用由法定医疗保险承担。在开始使用超出批准适应症范围的大麻类药物进行治疗之前，必须向健康保险公司提交报销申请。大麻类药物主要用于治疗慢性疼痛。开具大麻类药物时需遵守一些规则：《麻醉药品处方条例》第9条规定的信息必须完整、清晰。在一项为期五年的随访调查中收集了大麻类药物治疗效果和安全使用的数据。根据这项调查的初步中期结果，许多副作用会影响患者的警觉性。跌倒风险增加，尤其是老年患者。从中期来看，由于大麻类成品药的获批，上述特殊规定应会变得不再必要。
